High Prevalence of Chronic Diseases and Approval and Launch of New Products to Augment Growth of Array Market
The high prevalence of chronic diseases is expected to propel growth of the array market. For instance, according to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045.
Moreover, approval and launch of new products is also expected to aid in growth of the market. For instance, in March 2020, Agilent Technologies Inc. launched Agilent GenetiSure Cyto microarrays for prenatal and postnatal research. Similarly, the company launched three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal research.
Accuracy of arrays in determining the presence of pathogens in cannabis is expected to offer lucrative growth opportunities for players in the global array market. For instance, according to a November 2019 study results released by PathogenDx, Inc., end-point PCR technologies such as Sequencing and DNA microarray are more accurate in determining the presence of pathogens in cannabis.
Among regions, Europe is expected to witness significant growth in the array market, owing to growing pharmaceutical sector. For instance, according to The European Federation of Pharmaceutical Industries and Associations’ Key Data 2019, the pharmaceutical sector in Europe was valued at US$ 139, 287 million in 2000, which increased to US$ 284, 028 million (est.) in 2018.
The array market is witnessing several M&A activities. For instance, in December 2019, Oncology Pharma, Inc. signed a Letter of Intent to acquire at least a 50% stake in Diagnomics, Inc., a private CLIA certified & CAP accredited private molecular Genomics lab and provider of DNA microarrays, Next Generation Sequencing, and real-time PCR solutions
Competitive Analysis
Major players operating in the array market include, Affymetrix, Inc., Diagnomics, Inc., PathogenDx, Inc., Illumina, Inc., Naffymetrix Inc., Roche Diagnostics Inc., Bio-Rad Laboratories, Life Technologies, Caliper Life Sciences, Perkin Elmer, Inc., Siemens Healthineers, Agilent Technologies Inc., PathogenDx, Inc., and Twist Bioscience Corporation.
Major players operating in the array market are focused on R&D of new products to expand their product portfolio. For instance, in December 2019, PathogenDx, Inc. was awarded two US Patents for Tandem PCR + Microarray Hybridisation technology
Comments
Post a Comment